Sour Cherry Seed Extract Topical Formulation for Osteoarthritis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for osteoarthritis, such as analgesics and biotherapeutic drugs, fail to effectively address the underlying pathomechanisms of the disease, including inflammation and cartilage destruction, and are often costly and associated with severe side effects.

Innovation Solution

A topical biotherapeutic composition comprising a combination of sour cherry seed extract (SCE) and sour cherry seed oil (SCO) is developed, which induces heme oxygenase-1 (HO-1) activity, thereby reducing joint pain, inflammatory cytokine production, and oxidative stress, and inhibiting disease-associated inflammatory mediator production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional analgesics and biotherapeutic drugs are used to treat osteoarthritis, then pain management and inflammatory control are achieved, but the underlying pathomechanisms remain unaddressed and severe side effects occur

Engineering Contradiction:
Improveeffectiveness in addressing underlying pathomechanismsVSAvoidside effects
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces expensive, complex biotherapeutic drugs with a simple, natural topical formulation derived from sour cherry seeds. This natural formulation achieves therapeutic effects without the severe side effects associated with conventional drugs, effectively using a simple, accessible substance to replace complex pharmaceutical interventions

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent introduces HO-1 (heme oxygenase-1) as a mediator that naturally regulates inflammatory responses. The sour cherry seed formulation works by inducing HO-1 expression, which then acts as an endogenous mediator to control inflammation and protect against tissue damage, avoiding the need for direct administration of potent pharmaceutical agents

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If genetically engineered cytokine inhibitors are administered to OA patients, then inflammatory cytokine activity is reduced, but structural deterioration continues and severe side effects including cancer and immune impairment occur

Engineering Contradiction:
Improveinflammatory cytokine inhibitionVSAvoidsevere side effects including cancer and immune impairment
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the body's own inflammatory response into a beneficial protective mechanism by inducing HO-1 expression. Instead of suppressing inflammation with potent inhibitors that cause severe side effects, the formulation harnesses the body's natural anti-inflammatory pathways through HO-1, which produces protective molecules like carbon monoxide and bilirubin that actively protect tissues

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent enables the body to self-regulate inflammation through induced HO-1 expression. The sour cherry seed formulation triggers the body's own protective mechanisms, allowing endogenous cells to produce anti-inflammatory mediators and protect against tissue damage without requiring continuous external administration of potent pharmaceutical agents

Inventive Principle:
Principle #25Self-service

3Reliability

If corticosteroids and non-steroidal anti-inflammatories are used to control inflammation, then inflammatory symptoms are suppressed, but severe toxicity occurs particularly over extended time periods

Engineering Contradiction:
Improveinflammatory controlVSAvoidsevere toxicity
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces toxic corticosteroids and NSAIDs with a safe, natural topical formulation from sour cherry seeds. This formulation provides sustained anti-inflammatory effects through HO-1 induction without the cumulative toxicity of conventional drugs, using simple natural compounds to replace potent but harmful pharmaceuticals

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent changes the mechanism of anti-inflammatory action from direct suppression of inflammatory pathways (which causes toxicity) to induction of protective HO-1 expression. This parameter change in the therapeutic approach shifts from inhibiting inflammation to actively protecting tissues, achieving anti-inflammatory effects without toxic side effects

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The SCE/SCO composition significantly reduces joint pain, decreases peripheral blood c-reactive protein levels, increases leukocyte HO-1 expression, and inhibits the production of inflammatory cytokines by CD3+ T lymphocytes, effectively addressing the underlying inflammatory processes in osteoarthritis.

Implementation Method 1

The SCE/SCO composition systemically increases the activity of HO-1, a major physiological protectant against oxidative stress

Methodology Applied
Scientific EffectEnzyme induction: Enzyme

Implementation Method 2

Oxidative stress, created by this degradative process, promotes emergence of senescent osteoarthritic osteoblasts

Methodology Applied
Scientific EffectOxidative stress reduction: Oxidation

Implementation Method 3

The production of inflammatory cytokines by activated CD3+ T lymphocytes offers an excellent 'choke point' for intervention in OA pathogenesis

Methodology Applied
Scientific EffectCytokine inhibition:

Data Source

PatentEP3200810B1Sour cherry topical biotherapeutic formulations, method of manufacture and medical use thereof in the treatment of human osteoarthritis symptoms
Publication Date: 2025.06.18 MAHMOUD FADIA F
  • EP3200810B1 patent drawingFigure 1
  • EP3200810B1 patent drawingFigure 2
  • EP3200810B1 patent drawingFigure 3

AI summary

A biotherapeutic anti-inflammatory composition, its method of manufacture and method of treatment of various diseases, the composition having an efficacious amount of solid sour cherry seed extract and sour cherry seed oil sufficient to inhibit production of disease-associated inflammatory cytokines by CD3+ T lymphocytes in a vertebrate mammal.